Perspectives for Targeting Ezrin in Cancer Development and Progression
Recent advances have been made in understanding molecular markers involved in cancer malignancy, resulting in better tumor staging and identifying new potential therapeutic targets. Ezrin (EZR), a member of the ezrin, radixin, moesin (ERM) protein family, is essential for linking the actin cytoskele...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-01-01
|
| Series: | Future Pharmacology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2673-9879/3/1/5 |
| _version_ | 1797611580934848512 |
|---|---|
| author | Jean Carlos Lipreri da Silva Hugo Passos Vicari João Agostinho Machado-Neto |
| author_facet | Jean Carlos Lipreri da Silva Hugo Passos Vicari João Agostinho Machado-Neto |
| author_sort | Jean Carlos Lipreri da Silva |
| collection | DOAJ |
| description | Recent advances have been made in understanding molecular markers involved in cancer malignancy, resulting in better tumor staging and identifying new potential therapeutic targets. Ezrin (EZR), a member of the ezrin, radixin, moesin (ERM) protein family, is essential for linking the actin cytoskeleton to the cell membrane and participates in the signal transduction of key signaling pathways such as Rho GTPases and PI3K/AKT/mTOR. Clinical and preclinical studies in a wide variety of solid and hematological tumors indicate that (i) EZR is highly expressed and predicts an unfavorable clinical outcome, and (ii) EZR inhibition reduces proliferation, migration, and invasion in experimental models. The development of pharmacological inhibitors for EZR (or the signaling mediated by it) has opened a new round of investigation, but studies are still limited. The scope of the present review is to survey studies on the expression and clinical impact of EZR in cancer, as well as studies that perform interventions on the function of this gene/protein in cancer cells, providing proof-of-concept of its antineoplastic potential. |
| first_indexed | 2024-03-11T06:30:44Z |
| format | Article |
| id | doaj.art-2302659d83fd4c95b7ee4e7c41e2ea6c |
| institution | Directory Open Access Journal |
| issn | 2673-9879 |
| language | English |
| last_indexed | 2024-03-11T06:30:44Z |
| publishDate | 2023-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Future Pharmacology |
| spelling | doaj.art-2302659d83fd4c95b7ee4e7c41e2ea6c2023-11-17T11:13:24ZengMDPI AGFuture Pharmacology2673-98792023-01-0131617910.3390/futurepharmacol3010005Perspectives for Targeting Ezrin in Cancer Development and ProgressionJean Carlos Lipreri da Silva0Hugo Passos Vicari1João Agostinho Machado-Neto2Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo 05508-000, BrazilDepartment of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo 05508-000, BrazilDepartment of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo 05508-000, BrazilRecent advances have been made in understanding molecular markers involved in cancer malignancy, resulting in better tumor staging and identifying new potential therapeutic targets. Ezrin (EZR), a member of the ezrin, radixin, moesin (ERM) protein family, is essential for linking the actin cytoskeleton to the cell membrane and participates in the signal transduction of key signaling pathways such as Rho GTPases and PI3K/AKT/mTOR. Clinical and preclinical studies in a wide variety of solid and hematological tumors indicate that (i) EZR is highly expressed and predicts an unfavorable clinical outcome, and (ii) EZR inhibition reduces proliferation, migration, and invasion in experimental models. The development of pharmacological inhibitors for EZR (or the signaling mediated by it) has opened a new round of investigation, but studies are still limited. The scope of the present review is to survey studies on the expression and clinical impact of EZR in cancer, as well as studies that perform interventions on the function of this gene/protein in cancer cells, providing proof-of-concept of its antineoplastic potential.https://www.mdpi.com/2673-9879/3/1/5ezrinezrin/radixin/moesin (ERM) protein familycancerantineoplastic agent |
| spellingShingle | Jean Carlos Lipreri da Silva Hugo Passos Vicari João Agostinho Machado-Neto Perspectives for Targeting Ezrin in Cancer Development and Progression Future Pharmacology ezrin ezrin/radixin/moesin (ERM) protein family cancer antineoplastic agent |
| title | Perspectives for Targeting Ezrin in Cancer Development and Progression |
| title_full | Perspectives for Targeting Ezrin in Cancer Development and Progression |
| title_fullStr | Perspectives for Targeting Ezrin in Cancer Development and Progression |
| title_full_unstemmed | Perspectives for Targeting Ezrin in Cancer Development and Progression |
| title_short | Perspectives for Targeting Ezrin in Cancer Development and Progression |
| title_sort | perspectives for targeting ezrin in cancer development and progression |
| topic | ezrin ezrin/radixin/moesin (ERM) protein family cancer antineoplastic agent |
| url | https://www.mdpi.com/2673-9879/3/1/5 |
| work_keys_str_mv | AT jeancarloslipreridasilva perspectivesfortargetingezrinincancerdevelopmentandprogression AT hugopassosvicari perspectivesfortargetingezrinincancerdevelopmentandprogression AT joaoagostinhomachadoneto perspectivesfortargetingezrinincancerdevelopmentandprogression |